Dishman Pharmaceuticals and Chemicals has reported 37.35% rise in consolidated net profit at Rs 31.29 crore for the quarter ended March 31. The company had posted net profit of Rs 22.78 crore for the quarter ended March 31, 2011.
The company’s net sales stood at Rs 350.18 crore for the quarter ended March 31, 2012, as against Rs 344.40 crore for the corresponding quarter in the previous fiscal.
Consolidated net profit of the company for the year ended March 31, 2012 however declined to Rs 56.76 crore, as against Rs 79.97 crore for the year ago period.
Dishman Pharmaceuticals and Chemicals is engaged in manufacturing of Bulk API, Intermediates, Specialties and Quats. The company has started production of a range of phase transfer catalysts and quaternary ammonium and phosphonium compounds in 1989.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: